TAK 915

Drug Profile

TAK 915

Alternative Names: TAK915

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class
  • Mechanism of Action Type 2 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 01 Aug 2016 Takeda completes a phase-I trial in Schizophrenia (In volunteers) in USA (NCT02461160)
  • 30 Apr 2016 Takeda completes a phase I trial in Healthy volunteers in USA (NCT02584569)
  • 27 Oct 2015 Takeda plans a phase I trial in Healthy volunteers in USA (NCT02584569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top